Lates News

Each AI express, Guojin Securities released a research report on March 29, giving Sichuan Shuangma (000935.SZ) a "buy" rating. The main reasons for the rating include: 1) the company is transforming towards the dual drive of "private placement cash cow + new growth in medicine"; 2) basic plate and safety margin: the private equity business has entered the harvest period, providing performance support and cash flow; 3) core growth pole: the medicine sector acquired Shenzhen Jianyuan, entering the polypeptide CDMO track; 4) The third driving force (valuation reshaping): business paradigm shift, moving from cyclical valuation to growth valuation. (Daily Economic News)